Indication
Cufence is indicated for the treatment of Wilson’s disease in patients intolerant to D-Penicillamine therapy, in adults and children aged 5 years or older.
Loading your page…
Loading your page…
Hepatolenticular Degeneration
Marketing Authorisation Holder: Univar Solutions BV
EMA Authorisation: 25/07/2019
INN: trientine dihydrochloride
AI Drug & Interaction Analysis
Free account required
Ask Osler about Cufence: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.